Contract grant sponsor: European Commission Framework 6; Contract grant number: LSHB-CT-2003–503428; Contract grant sponsor: GlaxoSmithKline; Contract grant sponsor: UK National Institute for Health Research of the Department of Health; Contract grant sponsor: NIMH; Contract grant number: N01MH90003; Contract grant sponsor: Innovative Medicines Initiative of the European Commission; Contract grant number: 115008; Contract grant sponsor: NIMH; Contract grant number: MH086026.
SELF-REPORT AND CLINICIAN-RATED MEASURES OF DEPRESSION SEVERITY: CAN ONE REPLACE THE OTHER?
Article first published online: 29 AUG 2012
© 2012 Wiley Periodicals, Inc.
Depression and Anxiety
Volume 29, Issue 12, pages 1043–1049, December 2012
How to Cite
Uher, R., Perlis, R. H., Placentino, A., Dernovšek, M. Z., Henigsberg, N., Mors, O., Maier, W., McGuffin, P. and Farmer, A. (2012), SELF-REPORT AND CLINICIAN-RATED MEASURES OF DEPRESSION SEVERITY: CAN ONE REPLACE THE OTHER?. Depress. Anxiety, 29: 1043–1049. doi: 10.1002/da.21993
- Issue published online: 3 DEC 2012
- Article first published online: 29 AUG 2012
- Manuscript Accepted: 27 JUL 2012
- Manuscript Revised: 25 JUL 2012
- Manuscript Received: 29 MAR 2012
- European Commission Framework 6. Grant Number: LSHB-CT-2003–503428
- UK National Institute for Health Research of the Department of Health
- NIMH. Grant Number: N01MH90003
- Innovative Medicines Initiative of the European Commission. Grant Number: 115008
- NIMH. Grant Number: MH086026
- clinical trials;
- mood disorders
It has been suggested that clinician-rated scales and self-report questionnaires may be interchangeable in the measurement of depression severity, but it has not been tested whether clinically significant information is lost when assessment is restricted to either clinician-rated or self-report instruments. The aim of this study is to test whether self-report provides information relevant to short-term treatment outcomes that is not captured by clinician-rating and vice versa.
In genome-based drugs for depression (GENDEP), 811 patients with major depressive disorder treated with escitalopram or nortriptyline were assessed with the clinician-rated Montgomery–Åsberg Depression Rating Scale (MADRS), Hamilton Rating Scale for Depression (HRSD), and the self-report Beck Depression Inventory (BDI). In sequenced treatment alternatives to relieve depression (STAR*D), 4,041 patients treated with citalopram were assessed with the clinician-rated and self-report versions of the Quick Inventory of Depressive Symptomatology (QIDS-C and QIDS-SR) in addition to HRSD.
In GENDEP, baseline BDI significantly predicted outcome on MADRS/HRSD after adjusting for baseline MADRS/HRSD, explaining additional 3 to 4% of variation in the clinician-rated outcomes (both P < .001). Likewise, each clinician-rated scale significantly predicted outcome on BDI after adjusting for baseline BDI and explained additional 1% of variance in the self-reported outcome (both P < .001). The results were confirmed in STAR*D, where self-report and clinician-rated versions of the same instrument each uniquely contributed to the prediction of treatment outcome.
Complete assessment of depression should include both clinician-rated scales and self-reported measures.